Amicus Therapeutics, Inc. (FOLD) Stock Analysis

Amicus Therapeutics, Inc. (FOLD) Healthcare & Pipeline Overview

Amicus Therapeutics, Inc. is a biotechnology company headquartered in Philadelphia, specializing in developing and commercializing medicines for rare diseases. Its primary commercial product, Galafold, targets Fabry disease, while its robust pipeline includes gene therapies for Pompe disease, CLN3, and CDKL5, addressing significant unmet medical needs within the rare disease landscape.

What Is the Investment Thesis for FOLD?

Amicus Therapeutics, Inc. presents a focused investment thesis centered on its established commercial product, Galafold, and a promising pipeline targeting high-need rare diseases. Galafold's continued market penetration for Fabry disease provides a stable revenue base, supported by a strong gross margin of 88.5%. The company's strategic focus on rare diseases, characterized by smaller patient populations but often higher pricing power and orphan drug designations, offers a defensible market position. Key growth catalysts include the advancement and potential commercialization of AT-GAA for Pompe disease, which represents a novel treatment paradigm with significant market potential. Further upside is tied to the progression of its gene therapy programs for CLN3 and CDKL5, which are in early clinical stages but target severe neurological disorders with limited current treatment options. While the company reported a negative profit margin of -4.3% and a high debt-to-equity ratio of 161.30, indicating ongoing R&D investments and leverage, its positive free cash flow of $0.05 billion suggests operational efficiency in managing its cash burn. The low Beta of 0.48 also indicates relatively lower volatility compared to the broader market, which may appeal to certain institutional investors seeking stability within the biotechnology sector.

Based on FMP financials and quantitative analysis

FOLD Key Highlights

Market capitalization stands at $4.55B, reflecting its valuation as a specialized biotechnology company in the rare disease space.

• Gross margin of 88.5% demonstrates strong product profitability, primarily driven by its commercial product, Galafold.
• Profit margin of -4.3% indicates ongoing significant investments in research and development for its pipeline, typical for a growth-oriented biotech firm.
• Debt-to-equity ratio of 161.30 suggests a reliance on debt financing, which is common in capital-intensive drug development.
• Free Cash Flow (FCF) of $0.05 billion highlights the company's ability to generate positive cash from operations despite being unprofitable, supporting its R&D efforts.

Who Are FOLD's Competitors?

FOLD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are FOLD's Key Strengths?

Commercialized product (Galafold) providing a revenue base and market presence in rare diseases.

• Strong gross margin (88.5%) indicating efficient production and pricing power for its commercial therapy.
• Diverse and innovative pipeline including gene therapies for severe neurological disorders.
• Strategic collaborations with leading academic institutions and pharmaceutical partners.

What Are FOLD's Weaknesses?

Negative profit margin (-4.3%) reflecting high R&D expenditures and current unprofitability.

• High debt-to-equity ratio (161.30) suggesting significant leverage and potential financial risk.
• Reliance on a limited number of commercial products for current revenue generation.
• Early-stage nature of several key pipeline assets means long development timelines and inherent risks.

What Could Drive FOLD Stock Higher?

FOLD catalyst: Potential positive clinical trial readouts for AT-GAA in Pompe disease, which could pave the way for regulatory submissions and commercialization.

• Advancement of the CLN3 gene therapy program (AT-GTX-502) through its Phase 1/2 clinical study, with potential for data updates on safety and efficacy.
• Continued global market expansion and increased patient penetration for Galafold in Fabry disease, driving revenue growth.
• Regulatory milestones or approvals for pipeline candidates in key markets, which would significantly de-risk development and unlock commercial potential.

What Are the Key Risks for FOLD?

Financial-distress signal — its Altman Z-Score of 1.34 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-11.6%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Clinical trial failures or unexpected safety concerns for pipeline candidates like AT-GAA or the gene therapies for CLN3 and CDKL5, which could lead to significant R&D write-offs.
• Intense competition in the rare disease market from established pharmaceutical companies and emerging biotechs, potentially impacting market share and pricing power.
• Regulatory delays or non-approvals for new therapies, extending development timelines and increasing costs without guaranteed market access.
• High debt-to-equity ratio (161.30) and negative profit margin (-4.3%) indicate financial leverage and ongoing unprofitability, which could strain resources if pipeline progress falters.
• Market access and reimbursement challenges for high-cost rare disease therapies, which could limit commercial uptake even after regulatory approval.

What Are the Growth Opportunities for FOLD?

• Growth opportunity 1: **Expansion of Galafold's Market Penetration for Fabry Disease**: Galafold is Amicus's commercial product for Fabry disease, an inherited disorder caused by a defective gene. The market for Fabry disease treatments is significant, with an estimated global market size projected to reach over $2 billion by the late 2020s. Amicus can drive growth by increasing patient identification, expanding geographic reach, and demonstrating the long-term benefits of Galafold. As an oral precision medicine, Galafold offers a convenient alternative to traditional enzyme replacement therapies, potentially leading to greater patient adherence and market share capture. Continued clinical data generation and physician education will be crucial for maximizing this opportunity.
• Growth opportunity 2: **Advancement and Commercialization of AT-GAA for Pompe Disease**: AT-GAA represents a novel treatment paradigm for Pompe disease, a severe and progressive muscle disorder. The global Pompe disease market is expected to exceed $1.5 billion by the early 2030s, driven by increasing diagnosis rates and demand for more effective therapies. If AT-GAA successfully navigates clinical trials and gains regulatory approval, it could significantly enhance Amicus's revenue streams. Its potential to offer improved efficacy and safety over existing enzyme replacement therapies positions it as a strong contender in this market, providing a substantial growth driver over the next five to ten years.
• Growth opportunity 3: **Development of CLN3 Gene Therapy for Batten Disease**: Amicus's CLN3 gene therapy program, currently in Phase 1/2 clinical study, targets CLN3 disease (a form of Batten disease), a devastating neurodegenerative disorder with very limited treatment options. The rare nature of this disease means a smaller patient population, but also potentially high value per patient and orphan drug incentives. Successful progression through clinical development and eventual commercialization could unlock a new, high-value revenue stream. The timeline for this opportunity is longer-term, likely beyond five years, but represents a significant future growth vector in the gene therapy space for severe neurological conditions.
• Growth opportunity 4: **Progression of CDKL5 Gene Therapy for Neurological Disorders**: The CDKL5 gene therapy program targets disorders related to the CDKL5 protein, which is essential for normal brain development. CDKL5 deficiency disorder is a rare, severe neurological condition, and a gene therapy could offer a transformative treatment. While still in early development, successful preclinical and clinical data could position Amicus as a leader in addressing this specific unmet medical need. The market for gene therapies targeting rare neurological disorders is rapidly expanding, with significant potential for premium pricing and accelerated regulatory pathways. This represents a long-term growth opportunity, contingent on successful clinical validation.
• Growth opportunity 5: **Leveraging Strategic Collaborations for Pipeline Acceleration**: Amicus has established key collaboration and license agreements with institutions like Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. These partnerships are crucial for accelerating research and development, particularly in complex areas like gene therapy. By leveraging external scientific expertise, technology platforms, and potentially funding, Amicus can de-risk its pipeline and bring new therapies to market more efficiently. These collaborations can also provide access to broader patient populations and facilitate global market access, enhancing the company's overall growth trajectory over the medium to long term.

What Are FOLD's Competitive Advantages?

• Specialization in rare diseases, which often benefits from orphan drug designations, providing market exclusivity and reduced competition.
• Proprietary oral precision medicine, Galafold, offering a differentiated treatment option for Fabry disease.
• Advanced pipeline of novel gene therapies and enzyme replacement therapies targeting complex genetic disorders.
• Strategic collaborations with leading research institutions, enhancing R&D capabilities and intellectual property.

What Does FOLD Do?

Amicus Therapeutics, Inc., incorporated in 2002 and headquartered in Philadelphia, Pennsylvania, is a dedicated biotechnology company committed to the discovery, development, and delivery of innovative medicines for individuals suffering from rare diseases. The company's foundational strategy revolves around addressing significant unmet medical needs through precision medicine and advanced therapeutic modalities. Its flagship commercial product is Galafold (migalastat), an oral precision medicine specifically approved for the treatment of adults diagnosed with Fabry disease who possess an amenable galactosidase alpha gene variant, as determined by in vitro assay data. Galafold represents a significant advancement in Fabry disease management, offering a targeted approach to a complex genetic disorder. Beyond its commercial success with Galafold, Amicus Therapeutics boasts a dynamic pipeline of product candidates. This includes AT-GAA, a novel treatment paradigm under development for Pompe disease, which aims to improve upon existing enzyme replacement therapies. The company is also at the forefront of gene therapy research, with programs such as CLN3, currently in a Phase 1/2 clinical study. This study is evaluating the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3, a severe neurodegenerative lysosomal storage disorder. Additionally, Amicus is developing a gene therapy for CDKL5, targeting a gene on the X-chromosome that encodes the CDKL5 protein, crucial for normal brain development. These pipeline initiatives are bolstered by strategic collaboration and license agreements with prominent institutions such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline, underscoring Amicus's commitment to leveraging external expertise to accelerate its research and development efforts in the rare disease space.

What Products and Services Does FOLD Offer?

• Discover, develop, and deliver medicines for rare diseases, focusing on areas with high unmet medical needs.
• Commercialize Galafold, an oral precision medicine for adults with Fabry disease and amenable gene variants.
• Develop AT-GAA, a novel treatment paradigm for Pompe disease, aiming to improve enzyme replacement therapy.
• Conduct Phase 1/2 clinical studies for CLN3 gene therapy (AT-GTX-502) for patients with CLN3 Batten disease.
• Research and develop gene therapies for CDKL5 deficiency disorder, impacting normal brain development.
• Engage in strategic collaboration and license agreements with academic institutions and pharmaceutical companies to advance its pipeline.

How Does FOLD Make Money?

• Generate revenue primarily through the sale of its commercial product, Galafold, for Fabry disease.
• Invest significantly in research and development of novel therapies, particularly gene therapies and enzyme replacement therapies for rare diseases.
• Seek regulatory approvals for its pipeline candidates, which upon commercialization, will contribute to future revenue streams.
• Utilize strategic partnerships and licensing agreements to share development costs and expand therapeutic reach.

What Industry Does FOLD Operate In?

Amicus Therapeutics operates within the highly specialized and competitive biotechnology industry, specifically focusing on rare diseases. This niche segment is characterized by significant unmet medical needs, often leading to expedited regulatory pathways and premium pricing for approved therapies. The broader biotechnology market is experiencing robust growth driven by advancements in genomics, gene therapy, and precision medicine, all areas where Amicus is actively engaged. The competitive landscape for rare diseases involves both large pharmaceutical companies with dedicated orphan drug divisions and smaller, agile biotech firms. Amicus differentiates itself through its oral precision medicine, Galafold, and its pipeline of novel gene therapies. The company's strategy aligns with the industry trend of developing highly targeted treatments for genetically defined patient populations, aiming to capture substantial market share in specific disease areas rather than broad markets. This focus allows for deeper scientific expertise and potentially stronger intellectual property protection, crucial for long-term success in this capital-intensive sector.

Who Are FOLD's Key Customers?

• Adult patients diagnosed with Fabry disease who have amenable galactosidase alpha gene variants.
• Patients suffering from Pompe disease, once AT-GAA is commercialized.
• Patients with CLN3 disease (Batten disease) and CDKL5 deficiency disorder, upon successful development and approval of gene therapies.
• Healthcare providers, including specialists and clinics, who prescribe and administer treatments for rare genetic disorders.

Over the past six months, Amicus Therapeutics, Inc. insiders filed 30 SEC Form 4 transactions — 30 sales and 0 purchases. On net that is roughly 1.4M shares disposed (about $14.8M), a signal worth weighing alongside the fundamentals.

Quarterly Financial Performance: Amicus Therapeutics, Inc.

Revenue for Amicus Therapeutics, Inc. came in at $185.2M during Dec 2025, a 9.6% improvement versus the preceding quarter. The company recorded net income of $1.7M, with diluted EPS of $0.01. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, FOLD averaged $-0.02 in diluted EPS.

FOLD Valuation & Market Position

With a $4.55B market cap, Amicus Therapeutics, Inc. sits in the mid-cap segment of the market. Analyst price targets span from $13.00 to $19.00, with a consensus of $14.86. At the current price of $14.49, that implies approximately 3% upside potential.

Return on equity for Amicus Therapeutics, Inc. stands at -11.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.5%, showing how much profit it generates from its asset base. FOLD trades at a trailing price-to-earnings ratio of 17.69, below the Healthcare sector average of ~21.50x. A current ratio of 2.84 indicates the company holds enough short-term assets to cover its near-term obligations.

Amicus Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.34 places it in the distress zone, a signal of elevated financial risk.

Amicus Therapeutics, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 311.6% below estimates on average.

Wall Street analysts project Amicus Therapeutics, Inc. revenue of about $753.7M for fiscal 2026, with EPS near $0.36. The estimate reflects 3 contributing analysts.

Company Profile

Amicus Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Philadelphia, US. The company is led by CEO Bradley L. Campbell. FOLD has traded publicly since 2007.

FOLD Financials

FOLD Latest News

Amicus Therapeutics, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources